宝济药业-B:国家药监局批准KJ101在中国开展胃黏液清除临床试验

美股速递
Mar 12

宝济药业-B宣布,其研发的创新药KJ101已获得中国国家药品监督管理局(NMPA)的临床试验批准,将在中国开展针对胃黏液清除的临床研究。这一进展标志着公司在消化系统疾病治疗领域迈出重要一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10